SLONIN JONATHAN 4
4 · Pacira BioSciences, Inc. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Pacira (PCRX) CMO Jonathan Slonin Receives RSU Award
What Happened
Jonathan Slonin, Chief Medical Officer of Pacira BioSciences (PCRX), received a grant of 54,546 restricted stock units (RSUs) on February 11, 2026. The reported acquisition price is $0.00 and the filing lists the transaction as an award (code A). These RSUs represent contingent rights to receive common shares in the future rather than immediately issued shares.
Key Details
- Transaction date and type: 2026-02-11 — Award/grant of 54,546 RSUs (code A) at $0.00.
- Report filed: Form 4 filed 2026-02-13 (appears timely; Form 4 is generally due within two business days).
- Shares owned after transaction: Not specified in the provided filing summary.
- Footnote: F1 — RSUs vest in four equal annual installments beginning February 15, 2027, contingent on continuous service; each RSU equals the right to one share.
Context
RSUs are compensation awards that convert into actual shares only upon vesting; they do not represent immediate market purchases or sales. Because vesting here is spread over four years and is service-contingent, this grant reflects typical long-term incentive compensation rather than an immediate change in Slonin’s publicly tradable holdings.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-11+54,546→ 226,901.175 total
Footnotes (1)
- [F1]Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.